CAM
SRPT icon

Costello Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Costello Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59K Hold
200
– – ﹤0.01% 619
2026
Q1 		$4.35K Hold
200
– – ﹤0.01% 576
2025
Q4 		$4.3K Hold
200
– – ﹤0.01% 574
2025
Q3 		$3.85K Hold
200
– – ﹤0.01% 569
2025
Q2 		$3.42K Hold
200
– – ﹤0.01% 596
2025
Q1 		$12.8K Buy
+200
New +$21.1K 0.01% 425

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Costello Asset Management's SRPT Position: Q2 2026 in Review

Costello Asset Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 200 shares worth $3.59K. The position accounts for ﹤0.01% of the portfolio, ranked #619.

Costello Asset Management first reported a position in SRPT in Q1 2025 and has held it in 6 quarters since. The position peaked at $12.8K in Q1 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Costello Asset Management held 200 shares of Sarepta Therapeutics worth $3.59K as of Q2 2026.
  • Costello Asset Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Costello Asset Management's portfolio in Q2 2026, its #619 holding.
  • Costello Asset Management first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Costello Asset Management's Sarepta Therapeutics position peaked at $12.8K in Q1 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Costello Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.